Find Camonsertib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Rp-3500, 2417489-10-0, Rp3500, Camonsertib [inn], Camonsertib [usan], Camonsertib (rp-3500)
Molecular Formula
C21H26N6O3
Molecular Weight
410.5  g/mol
InChI Key
YIHHYCIYAIVQKX-YNOVCBQDSA-N
FDA UNII
S1Z7Y5G56T

Camonsertib
Camonsertib is an orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, camonsertib selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival. It is activated by DNA damage caused during DNA replication-associated stress.
1 2D Structure

Camonsertib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1R,5S)-3-[6-[(3R)-3-methylmorpholin-4-yl]-1-(1H-pyrazol-5-yl)pyrazolo[3,4-b]pyridin-4-yl]-8-oxabicyclo[3.2.1]octan-3-ol
2.1.2 InChI
InChI=1S/C21H26N6O3/c1-13-12-29-7-6-26(13)19-8-17(21(28)9-14-2-3-15(10-21)30-14)16-11-23-27(20(16)24-19)18-4-5-22-25-18/h4-5,8,11,13-15,28H,2-3,6-7,9-10,12H2,1H3,(H,22,25)/t13-,14-,15+,21?/m1/s1
2.1.3 InChI Key
YIHHYCIYAIVQKX-YNOVCBQDSA-N
2.1.4 Canonical SMILES
CC1COCCN1C2=NC3=C(C=NN3C4=CC=NN4)C(=C2)C5(CC6CCC(C5)O6)O
2.1.5 Isomeric SMILES
C[C@@H]1COCCN1C2=NC3=C(C=NN3C4=CC=NN4)C(=C2)C5(C[C@H]6CC[C@@H](C5)O6)O
2.2 Other Identifiers
2.2.1 UNII
S1Z7Y5G56T
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Rp-3500

2. 2417489-10-0

3. Rp3500

4. Camonsertib [inn]

5. Camonsertib [usan]

6. Camonsertib (rp-3500)

7. Atr Inhibitor 4;camonsertib

8. S1z7y5g56t

9. Chembl5095260

10. Schembl23515008

11. Schembl23515085

12. Gtpl12073

13. Rp 3500 [who-dd]

14. Rp 3500

15. 8-oxabicyclo[3.2.1]octan-3-ol, 3-[6-[(3r)-3-methyl-4-morpholinyl]-1-(1h-pyrazol-3-yl)-1h-pyrazolo[3,4-b]pyridin-4-yl]-, (3-endo)-

16. Ex-a6416

17. Nsc841442

18. Nsc-841442

19. Ms-27079

20. Cs-0226170

21. F83116

22. (1r, 5s)-3-[6-[(3r)-3-methylmorpholin-4-yl]-1-(1h-pyrazol-5-yl)pyrazolo[3, 4-b]pyridin-4-yl]-8-oxabicyclo[3.2.1]octan-3-ol

23. (1r,3r,5s)-3-{6-[(3r)-3-methylmorpholin-4-yl]-1-(1hpyrazol-3-yl)-1h-pyrazolo[3,4-b]pyridin-4-yl}-8-oxabicyclo[3.2.1]octan-3-ol

24. (1r,3r,5s)-3-6-[(3r)-3-methylmorpholin-4-yl]-1-(1hpyrazol-3-yl)-1h-pyrazolo[3,4-b]pyridin-4-yl-8-oxabicyclo[3.2.1]octan-3-ol

25. (1r,5s)-3-[6-[(3r)-3-methylmorpholin-4-yl]-1-(1h-pyrazol-5-yl)pyrazolo[3,4-b]pyridin-4-yl]-8-oxabicyclo[3.2.1]octan-3-ol

2.4 Create Date
2021-08-21
3 Chemical and Physical Properties
Molecular Weight 410.5 g/mol
Molecular Formula C21H26N6O3
XLogP31.6
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count3
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area101
Heavy Atom Count30
Formal Charge0
Complexity628
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 2417489-10-0 / Camonsertib API manufacturers, exporters & distributors?

Camonsertib manufacturers, exporters & distributors 1

14

PharmaCompass offers a list of Camonsertib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Camonsertib manufacturer or Camonsertib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Camonsertib manufacturer or Camonsertib supplier.

PharmaCompass also assists you with knowing the Camonsertib API Price utilized in the formulation of products. Camonsertib API Price is not always fixed or binding as the Camonsertib Price is obtained through a variety of data sources. The Camonsertib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Camonsertib

Synonyms

Rp-3500, 2417489-10-0, Rp3500, Camonsertib [inn], Camonsertib [usan], Camonsertib (rp-3500)

Cas Number

2417489-10-0

Unique Ingredient Identifier (UNII)

S1Z7Y5G56T

About Camonsertib

Camonsertib is an orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, camonsertib selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival. It is activated by DNA damage caused during DNA replication-associated stress.

Camonsertib Manufacturers

A Camonsertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Camonsertib, including repackagers and relabelers. The FDA regulates Camonsertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Camonsertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Camonsertib Suppliers

A Camonsertib supplier is an individual or a company that provides Camonsertib active pharmaceutical ingredient (API) or Camonsertib finished formulations upon request. The Camonsertib suppliers may include Camonsertib API manufacturers, exporters, distributors and traders.

Camonsertib GMP

Camonsertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Camonsertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Camonsertib GMP manufacturer or Camonsertib GMP API supplier for your needs.

Camonsertib CoA

A Camonsertib CoA (Certificate of Analysis) is a formal document that attests to Camonsertib's compliance with Camonsertib specifications and serves as a tool for batch-level quality control.

Camonsertib CoA mostly includes findings from lab analyses of a specific batch. For each Camonsertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Camonsertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Camonsertib EP), Camonsertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Camonsertib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty